AGPAT3 Antibody

Basic Research Questions

• What is AGPAT3 and what are its primary biological functions?

  AGPAT3 catalyzes the conversion of lysophosphatidic acid (LPA) to phosphatidic acid (PA) by incorporating an acyl moiety at the sn-2 position of the glycerol backbone. This enzymatic reaction is critical for glycerophospholipid and triglyceride biosynthesis, positioning AGPAT3 as a key regulator of lipid metabolism . The enzyme demonstrates substrate specificity, acting on LPA containing fatty acids C16:0-C20:4 at the sn-1 position, with a notable preference for arachidonoyl-CoA as an acyl donor .

  AGPAT3 exhibits tissue-specific expression patterns, with highest levels in testis, kidney, and liver, and intermediate expression in adipose tissue, heart, and skeletal muscle, suggesting diverse physiological roles . The enzyme localizes primarily to the endoplasmic reticulum and Golgi complex, where it regulates membrane structure and vesicular trafficking through modulation of phospholipid composition .

  Recent knockout studies have uncovered AGPAT3's involvement in multiple biological processes:

  • Adipocyte differentiation and adipose tissue development, with male AGPAT3-knockout mice exhibiting reduced body weight and decreased white and brown adipose tissue mass

  • Visual function, with knockout mice demonstrating retinal abnormalities and impaired vision due to reduced docosahexaenoic acid-containing phospholipids in the retina

  • Neuronal migration and development, with AGPAT3 deficiency causing significant migration defects in embryonic mouse brain and potentially underlying intellectual disability in humans

  • Cancer drug resistance, where AGPAT3 overexpression correlates with cisplatin resistance in ovarian cancer cells through activation of the mTORC1 signaling pathway

• What types of AGPAT3 antibodies are available for research applications?

  A variety of AGPAT3 antibodies are available to researchers, differentiated by several key characteristics:

  Antibody Catalog #	Target Region	Host	Clonality	Applications	Species Reactivity	Conjugation
  ABIN7142027	AA 148-304	Rabbit	Polyclonal	WB, ELISA, IHC	Human	Unconjugated
  ABIN7142030	AA 148-304	Rabbit	Polyclonal	ELISA	Human	HRP-conjugated
  RB22578	AA 241-269	Rabbit	Polyclonal	WB, IHC(p), FACS	Human	Unconjugated
  Not specified	AA 155-259	Mouse	Polyclonal	WB, ELISA	Human	Unconjugated
  Not specified	AA 145-194	Rabbit	Polyclonal	WB	Human, multiple species	Unconjugated
  Not specified	AA 145-310	Rabbit	Polyclonal	WB	Human	Unconjugated
  Proteintech 25723-1-AP	Not specified	Rabbit	Polyclonal	WB, ELISA	Human, Mouse, Rat	Unconjugated
  ab211435	AA 100-200	Rabbit	Polyclonal	IHC-P, WB	Human	Unconjugated
  ab135887	Not specified	Rabbit	Polyclonal	WB	Human	Unconjugated

  Most available antibodies are polyclonal and generated in rabbits, targeting various epitope regions throughout the AGPAT3 protein . The choice of target region is particularly important when investigating specific protein domains or when certain epitopes might be masked due to protein interactions or post-translational modifications. The majority of antibodies are validated for Western blotting applications, with several also applicable for ELISA, immunohistochemistry, and flow cytometry techniques .

  Most commercially available antibodies target human AGPAT3, with some showing cross-reactivity with mouse and rat orthologs. This cross-species reactivity is particularly valuable for translational research comparing findings between model organisms and human samples .

• What are the recommended protocols for AGPAT3 antibody application in Western blotting?

  For optimal AGPAT3 detection by Western blotting, researchers should follow these methodological guidelines:

  Sample preparation:

  • Harvest cells/tissues and lyse in appropriate buffer (RIPA buffer works well for most applications)

  • Include protease inhibitor cocktail to prevent degradation

  • Quantify protein concentration using Bradford or BCA assay

  • Adjust sample concentration to 1-2 μg/μl and mix with Laemmli buffer

  SDS-PAGE separation:

  • Load 20-30 μg protein per lane on 10-12% SDS-PAGE gel

  • Include positive control tissues (testis shows high expression)

  • Separate proteins at 100-120V until adequate resolution is achieved

  Transfer and immunoblotting:

  • Transfer to PVDF or nitrocellulose membrane (100V for 60-90 minutes or using turbo transfer systems)

  • Block with 5% BSA or non-fat milk in TBS/TBST for 30-60 minutes

  • Incubate with primary AGPAT3 antibody at recommended dilution:

    • Typically 1:500-1:2000 dilution (e.g., Proteintech 25723-1-AP at 1:1000)

    • Incubate overnight at 4°C for optimal results

  • Wash 3× with TBST, 5-10 minutes each

  • Incubate with appropriate HRP-conjugated secondary antibody (1:5000-1:10000) for 1 hour

  • Wash thoroughly and develop using ECL substrate

  Expected results:

  • AGPAT3 typically appears at 36-40 kDa (versus calculated 43 kDa)

  • Band intensity varies by tissue type, with strongest expression in testis, kidney, and adipose tissue

  • Multiple bands may indicate splice variants or post-translational modifications

  Special considerations:

  • For phosphorylation studies, include phosphatase inhibitors (sodium orthovanadate, sodium fluoride)

  • When comparing expression levels, ensure equal loading with housekeeping proteins like β-actin

  • Consider native conditions if studying protein-protein interactions that might affect antibody binding

• What methods should be used to validate AGPAT3 antibody specificity?

  Validation of AGPAT3 antibody specificity is crucial for reliable results. Researchers should implement these methodological approaches:

  Genetic validation:

  • Use CRISPR-Cas9 to generate AGPAT3 knockout cell lines

  • Apply siRNA or shRNA for transient knockdown (demonstrated effective in cancer cell lines)

  • Test antibody reactivity in tissues from AGPAT3 knockout mice

  Expression validation:

  • Correlate protein detection with mRNA expression levels via RT-qPCR

  • Overexpress wild-type AGPAT3 and confirm increased signal intensity

  • Express tagged versions (V5, FLAG) and co-detect with tag-specific antibodies

  Published research has validated antibody specificity through:

  • Western blot analysis showing absence of AGPAT3 protein in HEK293T cells expressing a nonsense mutant (p.Tyr249Ter)

  • shRNA-mediated downregulation of AGPAT3 in A2780cp cells resulting in reduced band intensity

  • Knockout mice studies showing absence of reactivity in tissues that normally express high levels of AGPAT3

  Technical controls:

  • Include blocking peptide competition to demonstrate specificity

  • Test in tissues/cells known to express (testis) or lack AGPAT3

  • Run parallel blots with different antibodies targeting distinct epitopes

  For comprehensive validation, researchers should employ at least two independent methods (e.g., genetic manipulation and expression correlation) to confirm antibody specificity before proceeding with experimental applications.

• How should researchers select appropriate AGPAT3 antibodies for different experimental applications?

  Selecting the optimal AGPAT3 antibody requires careful consideration of several factors:

  Application compatibility:

  • For Western blotting: Antibodies recognizing denatured epitopes work best

  • For immunoprecipitation: Choose antibodies that recognize native protein conformation

  • For IHC/IF: Select antibodies validated for fixed tissue specimens

  • For flow cytometry: Ensure antibodies recognize cell-surface accessible epitopes or include permeabilization

  Epitope considerations:

  • Target region accessibility: Some epitopes may be masked in protein complexes

  • Domain-specific questions: Select antibodies targeting regions of specific interest

  • Species conservation: For cross-species studies, target highly conserved regions

  Experimental conditions:

  • Fixation method: Different antibodies may perform differently with PFA versus methanol fixation

  • Buffer compatibility: Some epitopes are sensitive to specific detergents or pH conditions

  • Signal amplification needs: Consider HRP-conjugated options for enhanced sensitivity

  Validation status:

  • Prioritize antibodies with validation in your specific application

  • Evaluate published literature using the antibody for similar questions

  • Consider knockout/knockdown validation data provided by manufacturers

  Technical specifications:

  • Required dilution range (cost-effectiveness for large studies)

  • Storage and stability considerations

  • Lot-to-lot consistency (particularly important for longitudinal studies)

  A systematic selection approach would first identify antibodies validated for your intended application, then evaluate epitope accessibility relevant to your research question, and finally consider practical aspects such as species reactivity and technical specifications.

Advanced Research Questions

• How can AGPAT3 antibodies be used to investigate its role in cancer drug resistance mechanisms?

  Recent research has implicated AGPAT3 in cancer drug resistance, particularly in ovarian cancer. AGPAT3 antibodies can be strategically employed to investigate this phenomenon:

  Expression analysis in drug resistance models:

  • Western blot analysis using AGPAT3 antibodies (Proteintech 25723-1-AP, 1:1000 dilution) revealed significantly elevated AGPAT3 protein levels in cisplatin-resistant A2780cp ovarian cancer cells compared to sensitive A2780 cells

  • This differential expression was confirmed at both protein and mRNA levels through RT-qPCR analysis

  Pathway interaction studies:

  • Combined detection of AGPAT3 and mTOR pathway components demonstrated that increased AGPAT3 expression correlates with enhanced mTORC1 activation

  Cell Line Condition	AGPAT3 Expression	p-mTOR/mTOR Ratio	p-S6K/S6K Ratio	Cisplatin IC50 (μM)
  A2780 (sensitive)	Low	Low	Low	34.08
  A2780cp (resistant)	High	High	High	62.62
  A2780 + AGPAT3 overexpression	Increased	Increased	Increased	38.21 (from 31.2)
  A2780cp + AGPAT3 knockdown	Decreased	Decreased	Decreased	Not reported

  Functional validation studies:

  • Following genetic manipulation, AGPAT3 antibodies confirmed successful overexpression or knockdown

  • Overexpression of AGPAT3 in sensitive A2780 cells increased cisplatin IC50 from 31.2 to 38.21 μM

  • Flow cytometry analysis showed AGPAT3 overexpression:

    • Increased cell survival rate under cisplatin treatment

    • Reduced apoptosis rate under cisplatin treatment

    • Increased percentage of cells in G2/M phase from 8.53% to 17.05% during cisplatin exposure

  Mechanistic investigations:

  • Western blot analysis of phosphorylated versus total mTOR and S6K showed that AGPAT3 overexpression increased their phosphorylation ratios

  • This suggests AGPAT3 may confer cisplatin resistance through activation of the mTORC1 pathway

  These methodological approaches using AGPAT3 antibodies have established AGPAT3 as a potential therapeutic target for overcoming cisplatin resistance in ovarian cancer.

• What approaches can help resolve discrepancies when using different AGPAT3 antibodies in experimental studies?

  When encountering conflicting results with different AGPAT3 antibodies, researchers should implement these systematic troubleshooting approaches:

  Epitope mapping analysis:

  • Identify the specific binding regions of each antibody

  • Consult protein databases to determine if target regions overlap with:

    • Alternative splice variants or isoform-specific sequences

    • Regions subject to post-translational modifications

    • Protein-interaction domains that may be masked in certain contexts

  Experimental condition optimization:

  • Test multiple sample preparation methods:

    • Compare different lysis buffers (RIPA, NP-40, Triton X-100)

    • Evaluate denaturing vs. native conditions

    • Try various detergent concentrations

  • For IHC/IF applications, compare multiple fixation and antigen retrieval methods

  • Test different blocking agents (BSA vs. non-fat milk) to reduce non-specific binding

  Hierarchical validation framework:

  • Prioritize results from antibodies validated in knockout/knockdown systems

  • Cross-reference with orthogonal methods (mRNA expression)

  • Compare with functional assays and published literature

  Multi-antibody approach:

  • Use multiple antibodies targeting different epitopes in parallel experiments

  • Look for consistent patterns across different antibodies

  • When discrepancies occur, investigate whether they relate to specific protein regions

  Documentation and systematic analysis:

  • Maintain detailed records of conditions used with each antibody

  • Analyze patterns of discrepancy to identify potential variables

  • Perform side-by-side comparison experiments under identical conditions

  By implementing these methodological approaches, researchers can resolve discrepancies and select the most reliable antibodies for their specific experimental questions.

• How do AGPAT3 knockout phenotypes inform antibody-based detection approaches and functional studies?

  AGPAT3 knockout models provide valuable insights that complement antibody-based studies:

  Phenotypic characterization informs tissue selection:
  Recent studies in AGPAT3 knockout mice revealed distinctive phenotypes that guide antibody application:

  Parameter	Wild-type	AGPAT3 KO (Male)	AGPAT3 KO (Female)	Implication for Antibody Studies
  Body weight	Normal	Reduced	Slightly reduced	Target adipose tissue for analysis
  White adipose tissue	Normal	Decreased	Slightly decreased	Key tissue for antibody validation
  Brown adipose tissue	Normal	Decreased	Slightly decreased	Important for metabolic studies
  Plasma IGF1/insulin	Normal	Reduced	Reduced	Consider signaling pathway connections
  Vision	Normal	Impaired	Impaired	Include retinal tissue in analysis
  Male fertility	Normal	Reduced	N/A	Testis is high-expression control tissue

  Antibody validation strategy:

  • Knockout tissues provide definitive negative controls

  • Western blot analysis of knockout samples should show absence of specific bands

  • Any remaining bands represent non-specific binding to be avoided in interpretation

  Mechanistic insights guide experimental design:

  • AGPAT3-deficient mouse embryonic fibroblasts (MEFs) showed impaired adipogenesis

  • This suggests focusing antibody studies on adipocyte differentiation pathways

  • The finding that pioglitazone rescued adipogenic deficiency indicates potential connections to PPAR-γ signaling

  Neurological implications inform tissue selection:

  • Knockdown of Agpat3 in embryonic mouse brain caused neuronal migration deficits

  • Only 45.27% of transfected cells reached upper cortical layers vs. 86.55% in control

  • This indicates importance of examining neuronal tissues in developmental studies

  Knockout phenotypes have revealed previously unknown functions of AGPAT3 in adipose development, neuronal migration, and visual function, directing antibody-based studies toward these tissues and pathways for maximum relevance.

• How can researchers effectively use AGPAT3 antibodies to investigate its role in neurological development and disorders?

  Recent discoveries have implicated AGPAT3 in neurological function and development, with antibody-based approaches providing critical insights:

  Genetic disease correlation studies:

  • A nonsense variant c.747 C > A (p.Tyr249Ter) in AGPAT3 was identified in families with intellectual disability and retinitis pigmentosa (IDRP)

  • Western blot analysis using antibodies against V5-tagged AGPAT3 showed absence of mutant protein in HEK293T cells, indicating protein instability

  • This suggests examining protein expression levels in patient-derived cells with similar mutations

  Developmental expression mapping:

  • Immunohistochemistry can track AGPAT3 expression throughout brain development

  • Knockdown studies showed Agpat3 is essential for proper neuronal migration:

  Condition	Cells in Upper Cortical Layers (%)	Migration Defect
  Control	86.55%	None
  Agpat3 knockdown	45.27%	Severe

  Subcellular localization studies:

  • AGPAT3 localizes to endoplasmic reticulum and Golgi complex

  • Previous studies showed AGPAT3 knockdown resulted in Golgi fragmentation

  • Co-immunofluorescence with organelle markers can reveal altered subcellular distribution in neurological disorders

  Mechanistic investigations:

  • Combined with lipid profiling, antibody-based detection can correlate AGPAT3 expression with specific lipid alterations

  • In retinal tissue, AGPAT3 knockout led to reduced docosahexaenoic acid-containing phospholipids (PL-DHA)

  • This caused altered disc morphology, reduced outer segment length, and decreased outer nuclear layer thickness

  Therapeutic target exploration:

  • Following identification of AGPAT3's role in neuronal development, antibodies can track its expression during experimental interventions

  • This may help identify compounds that stabilize mutant proteins or compensatory mechanisms

  These methodological approaches highlight AGPAT3 as a critical factor in neuronal function and development, with implications for understanding and potentially treating neurodevelopmental disorders and retinal dystrophies.

• What methodological considerations are important when using AGPAT3 antibodies for studying its role in adipocyte differentiation and metabolism?

  Recent research has identified AGPAT3 as a key regulator of adipogenesis and metabolism, requiring specific approaches for antibody-based studies:

  Expression profiling during adipogenesis:

  • AGPAT3 expression increases during mouse and human adipogenesis

  • Western blot analysis should track expression at multiple timepoints during differentiation

  • Compare expression patterns in white versus brown adipose tissue from different anatomical locations

  Knockout phenotype characterization:

  • Male Agpat3 knockout mice exhibit significant reductions in:

    • Body weight

    • White and brown adipose tissue mass

    • Plasma insulin and IGF1 levels

    • Circulating lipid metabolites

  • Antibody-based tissue analysis should target these specific altered parameters

  Mechanistic pathway exploration:

  • Combine AGPAT3 antibody detection with markers of adipogenic differentiation

  • When studying the relationship between AGPAT3 and PPARγ pathways, consider:

    • Coordinate expression analysis

    • Response to PPARγ agonists (pioglitazone rescues differentiation defects)

    • Target gene expression correlation

  Subcellular fractionation approach:

  • Given AGPAT3's role in lipid metabolism, combine antibody detection with:

    • Membrane fraction analysis

    • Lipid droplet isolation

    • Endoplasmic reticulum and Golgi preparations

  Technical considerations specific to adipose tissue:

  • High lipid content can interfere with protein extraction

  • Optimize lysis buffers to effectively solubilize membrane-associated proteins

  • Consider delipidation steps before immunoprecipitation

  • For IHC, optimize fixation to preserve adipocyte morphology while maintaining epitope accessibility

  These methodological approaches enable comprehensive investigation of AGPAT3's role in adipose development and metabolism, with potential implications for understanding obesity, insulin resistance, and related metabolic disorders.